Paradoxical hormone responses of KPL-1 breast cancer cells in vivo: A significant role of angiogenesis in tumor growth

Oncology

Volumn 59, Issue 2, 2000, Pages 158-165

  Kurebayashi, Junichi ^a   Kunisue, Hironori ^a   Yamamoto, Shigeru ^a   Kurosumi, Masafumi ^b   Otsuki, Takemi ^a   Sonoo, Hiroshi ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

Author keywords

Angiogenesis; Antiestrogen; Apoptosis; Breast cancer; Medroxyprogesterone acetate; Resistance; TNP 470; Vascular endothelial growth factor

Indexed keywords

4 CHLOROBENZENESULFONIC ACID 4 CHLOROPHENYL ESTER; ANGIOGENESIS INHIBITOR; ANTIESTROGEN; ESTRADIOL; ESTRADIOL BENZOATE; FULVESTRANT; FUMAGILLOL CHLOROACETYLCARBAMATE; MEDROXYPROGESTERONE ACETATE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CONTROLLED STUDY; ESTROGEN ACTIVITY; FEMALE; HORMONE RESPONSE; HUMAN; HUMAN CELL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0033831805     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012154     Document Type: Article

References (22)

1. Katzenellenbogen BS, Montano MM, Ekena K, Herman ME, Mclnerney EM: Antiestrogens: Mechanisms of action and resistance in breast cancer. Breast Cancer Res Treat 1997;44:23-38.
2. Kurebayashi J, Kurosumi M, Sonoo H: A new human breast cancer cell line, KPL-1 secretes tumour-associated antigens and grows rapidly in female athymic nude mice. Br J Cancer 1995;71:845-853.
3. Kurebayashi J, Otsuki T, Yamamoto S, Kurosumi M, Nakata T, Akinaga S, Sonoo H: A pure antiestrogen, IC1 182, 780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro. Oncology 1998;55(suppl 1):23-34.
4. Kurebayashi J, Otsuki T, Kunisue H, Mikami Y, Tanaka K, Yamamoto S, Sonoo H: Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res 1999;90:977-981.
5. Hyder SM, Murthy L, Stancel GM: Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res 1998; 58:392-395.
6. Lange CA, Richer JK, Shen T, Horwitz KB: Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activatcd protein kinase pathways. J Biol Chem 1998;273:31308-31316.
7. Kurebayashi J, McLeskey SW, Johnson MD, Lippman ME, Dickson RB, Kern FG: Quantitative demonstration of spontaneous metastasis by MCF-7 human breast cancer cells co-transfected with fibroblast growth factor 4 and LacZ. Cancer Res 1993;53:2178-2187.
8. McLeskey SW, Zhang L, El-Ashry D, Trock BJ, Lopez CA, Kharbanda S, Tobias CA, Lorant LA, Hannum RS, Dickson RB, Kern FG: Tamoxifin-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen IC1 182, 780 and two aromatase inhibitors. Clin Cancer Res 1998;4: 697-711.
9. Zacharova G, Kubinova L: Stereological methods based on point counting and unbiased counting frames for two-dimensional measurements in muscles: Comparison with manual and image analysis methods. J Muscle Res Cell Motil 1995;16:295-302.
10. Kuwashima Y, Kobayashi Y, Kawarai A, Uehara T, Kurosumi M, Tanuma J, Shiromizu K, Matsuzawa M, Kishi K: Expression of bcl-2 and apoptotic DNA fragmentation in human endometrial adenocarcinoma cells. Anticancer Res 1996;16:3221-3224.
11. Kurebayashi J, Horiuchi R, Nakamura T, lino Y, Ishida T, Takigawa H, Izuo M: Effects of estrogen and endocrine therapeutic agents on the estrogen receptor, progesterone receptor and DNA synthesis in MCF-7 human breast cancer cells using the whole cell uptake method (in Japanese). Nippon Naibunpi Gakkai Zasshi 1987;63:1351-1363.
12. Mizukami Y, Tajiri K, Nonomura A, Noguchi M, Taniya T, Koyasaki N, Nakamura S, Matsubara F: Effects of tamoxifen, medroxypragesterone acetate and estradiol on tumor growth and oncogene expression in MCF-7 breast cancer cell line transplanted into nude mice. Anti-cancer Res 1991;11:1333-1338.
13. Kern FG, McLeskcy SW, Zhang L, Kurebayashi J, Liu Y, Ding IY, Kharbanda S, Chen D, Miller D, Cullen K, Paik S, Dickson RB: Transfected MCF-7 cells as a model for breast cancer progression. Breast Cancer Res Treat 1994;31: 153-165.
14. Tonetti DA, Jordan VC: The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer, J Stereoid Biochem Mol Biol 1997;62:119-128.
15. Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE: The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 1994;34:89-95.
16. Wolf DM, Jordan VC: Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res Treat 1994;31:117-127.
17. Gervaz P, Fontolliet C: Therapeutic potential of the antiangiogenesis drug TNP-470. Int J Exp Pathol 1998;79-359-362.
18. Sgroi DC, Teng S, Robinson G, LeVangie R, Hudson JR Jr, Elkahloun AG: In vivo gene expression profile analysis of human breast cancer progression. Cancer Res 1999;59:5656-5661.
19. Hilsenbeck SG, Friedrichs WE, Schiff R, O'Connell P, Hansen RK, Osborne CK, Fuqua SA: Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst 1999;91:453-459.
20. Bischoff ED, Heyman RA, Lamph WW: Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure. J Natl Cancer Inst 1999;91: 2118-2123.
21. Arteaga CL, Koli KM, Dugger TC, Clarke R: Reversal of tamoxifen resistance of human brest carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta. J Natl Cancer Inst 1999;91:46-53.
22. Gasparini G: The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 1999;58:17-38.